CardioMEMS welcomes $33m capital and new CFO:
This article was originally published in Clinica
Atlanta, Georgia-based CardioMEMS has completed a $33m series E financing led by Arcapita Ventures. Existing CardioMEMS shareholders, as well as new investors Deerfield Capital Management, Vision Capital Advisors, Aperture Venture Partners and Rockport Venture Securities, also participated in the round. CardioMEMS develops wireless sensing technologies is designed to eliminate the need for leads and batteries when managing severe chronic cardiovascular diseases. It intends to use the capital to advance clinical trials of its product.
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.